This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Need for Adult Vaccination in India
In countries with mass childhood vaccination through the NIP, a reduction in pneumococcal diseases is seen in the elderly due to herd effect. In these countries because of a reduction in diseases caused due to vaccine-type serotypes in the elderly, the coverage difference between PCV13 and PPSV23 is increasing. Such effect is yet to be seen in countries like India where mass childhood immunisation is in its early stages.1
According to a study by Rodriguez et al., among the immunocompetent adults admitted with CAP in the ICU, 22.1% had a fatal episode, despite >95% of the cases receiving adequate antibiotic therapy.2
Even in industrialised countries, the overall CFR for pneumococcal bacteraemia may reach 15% to 20% among adults and 30% to 40% among elderly patients despite appropriate antibiotic therapy and intensive care.3 In some groups with predisposing conditions, the CFR may exceed 50%, even when appropriate treatment is given. It has been noted that irrespective of the regions of the world, pneumococci have been showing increasing resistance to one or more of the commonly used antibiotics.3
In spite of the advances in medical science and the extensive use of PPSV23, over the last decades, the 12% to 13% CFR for pneumonia among the hospitalised patients in the United States which begins to increase at around 45 years of age, has remained constant through the 1950s to the present.4-7
The Geriatric Society of India has considered the role of both PPSV23 and PCV13 in the management of pneumococcal diseases in older adults above 50 years of age.8
Watch Dr. J. Venugopal’s video on how to implement an adult vaccination programme in the hospital.
PP-PNA-IND-0613
CAP, community-acquired pneumonia; CFR, case fatality rate; ICU, intensive care unit; IPD, invasive pneumococcal disease; NIP, national immunisation programme; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.